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Short sentence summary: Acute air pollution fluctuations are associated with increased exacerbation risk in patients with bronchiectasis. 
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Abstract: 
Introduction: 
In bronchiectasis, exacerbations are believed to be triggered by infectious agents, but often no pathogen can be identified.  We aimed to establish the effect 
of acute air pollution fluctuations on bronchiectasis exacerbations. 
Methods: 
We combined a case-crossover design with distributed lag models in an observational record linkage study.  Patients were recruited at Ninewells Hospital, 
Dundee, UK.  
Results: 
We recruited 432 patients with HRCT diagnosed and clinically confirmed bronchiectasis. After excluding days with missing air pollution data, the final model 
for PM10 was based on 6741 exacerbations from 430 patients and for NO2 it included 6248 exacerbations from 426 patients. For each 10µg/m³ increase in 
PM10 and NO2, the risk of having an exacerbation that same day increased significantly by 4.5% (95%CI: 0.9-8.3) and 3.2% (95%CI: 0.7-5.8) respectively. The 
overall increase in the risk of exacerbation for a 10μg/m3 increase in air pollutant concentration was 11.2% (95%CI: 6.0-16.8) for PM10 and 4.7% (95%CI: 0.1-
9.5) for NO2. Subanalysis showed significant higher relative risks during spring (PM10 1.198, 95%CI 1.102-1.303; NO2 1.146, 95%CI 1.035-1.268) and summer 
(PM10 2.142, 95%CI 1.785-2.570; NO2 1.352, 95%CI 1.140-1.602). 
Conclusions: 
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Acute air pollution fluctuations are associated with increased exacerbation risk in bronchiectasis.  
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Introduction 
Exacerbations are key events in the natural history of bronchiectasis and are associated with an increased risk of mortality, hospital admissions, lung 
function decline and death. 1,2 The causes of bronchiectasis exacerbations are not known, although they are presumed to be primarily bacterial or viral and 
guidelines recommend that all exacerbations are treated with antibiotics.3 Therapies aiming to reduce exacerbation frequency in bronchiectasis, however, 
have generally had modest effects and there is a high burden of exacerbation despite treatment. European registry data shows a median of two 
exacerbations per patient per year. 4 It is therefore important to gain further understanding of the causes of bronchiectasis exacerbations. Research shows 
that exposure to air pollution causes an inflammatory response. One study by McCreanor et al. showed that patients with asthma walking for two hours 
along a busy London street not only showed higher pollution exposure than their controls who walked through a nearby park, but they had decreased FEV1 
and FVC. These changes were accompanied by a significant increase in sputum myeloperoxidase, also known to be a key mediator in bronchiectasis.5,6 
Acute and chronic air pollution exposure have been linked with pulmonary exacerbations in patients suffering from cystic fibrosis. Acute fluctuations play a 
role in triggering pulmonary exacerbations in cystic fibrosis.7,8 Furthermore, proximity to major roads predicts exacerbations and annual average exposure 
to air pollution is associated with an increased risk of a pulmonary exacerbation and a decline in lung function.9,10 
For non-cystic fibrosis bronchiectasis (from now on referred to as bronchiectasis), data are scant. We recently showed that residential proximity to a major 
road and distance-weighted traffic density within 100 and 200 meters was associated with the risk of mortality.11 To our knowledge, there are no data on 
the effect of acute air pollution on bronchiectasis pulmonary exacerbations. 
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We aimed to establish the effect of acute air pollution fluctuations on bronchiectasis pulmonary exacerbations, using data from hospitals dedicated to the 
care of patients suffering from bronchiectasis not caused by cystic fibrosis. 
 
Materials and Methods  
 
Patient population and patient data linkage  
This manuscript describes a case-crossover observational record linkage study of patients with high resolution computed tomography (HRCT) diagnosed and 
clinically confirmed non-cystic fibrosis bronchiectasis attending a regional specialist clinic for bronchiectasis patients at Ninewells Hospital, Dundee, 
UK. Patients came from Aberdeen, Dundee, Kirkcaldy, Perth, and Falkirk. The study was approved by the local research ethics committee (study number: 
14/SS/1101) and all patients gave written informed consent to participate and for record linkage. Unique personal identifier codes were used to extract 
electronic medical records from an administrative database that covers more than 800,000 patients (approximately 16% of the Scottish population) from 
the date of first diagnosis of bronchiectasis (defined as the date of initial diagnostic HRCT scan). Linkage was performed by the Farr Institute, UK 
(http://www.farrinstitute.org/centre/Scotland)  and included data from January 1st 2000 to October 31st 2014 including all community drug prescriptions, 
hospital stays, diagnoses, interventions, laboratory tests (including sputum microbiology), radiology, diagnostic tests and deaths. Patients were also included 
in the Tayside Respiratory Disease Information System (TARDIS) which provides annual data on spirometry, microbiology, respiratory symptoms and 
respiratory treatments and has been used for multiple previous record linkage studies.12-14 The analysis excluded inhaled antibiotics and oral antibiotics 
prescribed as part of an eradication protocol. 
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Exacerbation definition 
During the study period there was no agreed definition of exacerbation of bronchiectasis, but most operational definitions previously required the acute 
prescription of antibiotics.1  During the study period, exacerbations were identified as an acute prescription of antibiotics for episodes coded as 
exacerbation of bronchiectasis or lower respiratory tract infection at the time of clinical presentation. This method of identification of exacerbations was 
prospectively validated against exacerbations treated in a prospective cohort and was 100% sensitive and 87% specific.  Severe exacerbations were defined 
as admissions to hospital for exacerbation of bronchiectasis. The first day of antibiotic prescription was considered to be the start date of the exacerbation. 
Exposure data 
Daily PM10 (particulate matter with a diameter smaller than 10 µm) and NO2 concentrations during the study period measured at the Aberdeen urban 
background site, which is part of the UK's Automatic Urban and Rural Network (AURN), were used for the analysis. Days with missing air pollution data were 
excluded. Because climate is a known confounder of the association between air pollution and respiratory diseases,15 data on mean air temperature and 
relative humidity were obtained from the UK Meteorological Office. For temperature, we used data from the measuring stations Dyce, Mylnefield, Kinross, 
Dalwhinnie, and Tyndrum for the postcode areas Aberdeen, Dundee, Kirkcaldy, Perth, and Falkirk, respectively. As humidity data are not available for 
Mylnefield and Kinross, humidity recorded at the stations of Strathallan Airfield and Leuchars were used for the postcode areas Dundee and Kirkcaldy, 
respectively. 
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Statistical Analysis 
The case-crossover design is widely used for analyzing short-term exposures with acute outcomes.16 It is a variant of the matched case-control study, where 
each subject serves as its own control so that known and unknown time-invariant confounders are inherently adjusted for by study design.17 This design 
samples only cases (exacerbations of bronchiectasis in this study) and compares each subject's exposure in a time period just before a case event (the 
hazard period) with that subject's exposure at other times (the control periods). Selection bias was avoided by applying a bidirectional time-stratified 
design.18 Control days are taken from the same calendar month and year as the case day (i.e. day of the bronchiectasis exacerbation), both before and after 
the case, thus controlling for long-term trends and season by design. Cases and controls were additionally matched by day of the week to control for any 
weekly patterns in air pollution or bronchiectasis. In the main analysis recurrent event data were pooled, considering exacerbations as the unit of analysis 
rather than persons and assuming that within-subject correlation is completely accounted for by subject-specific variables (observed or unobserved).19 
To investigate the association between bronchiectasis and air pollution exposure up to four days before the exacerbation, we combined the case-crossover 
design with distributed lag models, using separate models for PM10 and NO2. A distributed lag (non-linear) model is defined through a “cross-basis” function, 
which allows the simultaneous estimation of a (non-linear) exposure-response association and non-linear effects across lags, the latter termed lag-response 
association. This study applies recent extensions of the distributed lag models methodology beyond aggregated time series data,20 specifically implementing 
them in a conditional logistic regression model with individual-level exposure measures (at least for temperature). We assumed a linear association between 
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air pollution exposure and bronchiectasis and the lag structure was modelled with a natural cubic spline with three degrees of freedom (df). The knots in the 
lag space were set at equally spaced values in the log scale of lags to allow more flexible lag effects at shorter delays.21  
We also included a cross-basis for mean temperature in the model to capture the (potentially delayed) effects of heat and cold on bronchiectasis. The 
maximum lag was set to 25 days. We used a natural cubic spline with five df for the temperature–bronchiectasis function and a natural cubic spline with six 
df (with knots at equally spaced values in the log scale) for the lag structure. Spline knots for temperature were placed at equally spaced values of the actual 
temperature range to allow enough flexibility in the two ends of the temperature distribution.  
In a secondary analysis we studied the effects stratified by Pseudomonas aeruginosa infection status (yes or no), by bronchiectasis severity index (≤4: mild; 
5-8: moderate; ≥9: severe), and by deprivation index (divided into quintiles from the Scottish Index of Multiple Deprivation, a score from one to five where a 
lower index indicates higher deprivation) hospitalization (yes; no), chronic macrolide use at time of exacerbation (yes; no), and season (Mar-May: spring; 
Jun-Aug: summer; Sep-Nov: autumn, Dec-Feb; winter).1,22,23 In sensitivity analyses we increased the maximum lag to six. We also used an unconstrained 
distributed lag model, that is, a model in which each lag is entered as a separate variable.24 Because of the correlation between air pollution concentrations 
on days close together, the unconstrained distributed lag model will result in unstable estimates for the individual lags, but it is known as more flexible and 
less prone to bias for the estimate of the overall effect.24 We also explored the potential confounding by temperature by excluding the temperature cross-
basis from the model. We also explored potential confounding by humidity up to four days before the exacerbation (lag 0  to 4) by adding a cross-basis with 
a linear humidity-bronchiectasis function and a natural cubic spline with three df to model the lag structure. In a last sensitivity analysis, we used only one 
(the first) exacerbation per person, such that no assumption on the correlation among multiple events is needed.25  
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We calculated relative risks (RR) of bronchiectasis exacerbation for a 10 µg/m3 increase in air pollutant concentrations. This increase corresponds to a very 
realistic increase. In our analysis, this acccords to almost one standard deviation (Table 2). Reported estimates, computed as the overall cumulative risk 
accounting for the 0‒4 lag period, are presented as percent change in bronchiectasis with corresponding 95% confidence interval (CI). All analyses were 
performed with the statistical software R (R Foundation for Statistical Computing, Vienna, Austria) using the “dlnm” package.20  
Results 
 
Patient population 
Between January 6th 2000 and October 2nd 2014, 432 patients had a total of 7777 exacerbations. After excluding days with missing air pollution data, the 
final model for PM10 was based on 6741 exacerbations from 430 patients and the final model for NO2 included 6248 exacerbations from 426 patients. The 
population was predominantly female (60.2%) with a median age of 68 years (IQR 59-74). P. aeruginosa chronic infection during the follow-up period was 
seen in 13.9% of the patient population. Bronchiectasis Severity Index had an equal distribution of mild, moderate and severe risk patients (mild 28.1%; 
moderate 39.5%; severe 32.3%) (table 1). 
 
 
Ambient air pollution 
Table 2 shows descriptive statistics for the overall daily number of exacerbations, mean temperature, and ambient air pollutants. Mean temperature ranged 
from -11.5 to 21.3°C, with an average of 8.1°C. Average (range) PM10 and NO2 concentrations were 15.8 (1.0 to 82.6) µg/m3 and 25.5 (1.7 to 85.7) µg/m3 
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respectively. To highlight sufficient variation around a non-zero mean value as suggested in case-crossover studies,26 Table 2 also presents the “relevant 
exposure term,” which is the absolute difference between each pollutant’s level on the case day and its average concentrations over the control days. The 
Spearman correlation coefficient between PM10 and NO2 was 0.35. The correlation with mean temperature was 0.05 for PM10 and -0.30 for NO2. 
 
Effects of air pollution on exacerbation risk  
The three-dimensional plots show the association between bronchiectasis and PM10 and NO2 concentrations over the lag days (Figure 1). The effect of air 
pollution on bronchiectasis exacerbations was found to be acute, with highest RRs on the day of exposure (lag 0). Figure 2 presents the lag-specific RR for 
bronchiectasis associated with a 10 µg/m3 increase in air pollutant concentrations. Significant RR were observed at lag 0 and 1 for PM10, and at lag 0 for NO2. 
The risk of having an exacerbation increased by 4.5% (95% CI 0.9 to 8.3) and by 3.2% (95% CI 0.7 to 5.8) for each 10 µg/m³ increase in same-day (lag 0) PM10 
and NO2, respectively. Cumulative effects of air pollutant concentrations on bronchiectasis are presented in Table 3. The overall (lag 0-4) increase in the risk 
of an exacerbation for a 10 μg/m3 increase in air pollutant concentration was 11.2% (95% CI 6.0 to 16.8) for PM10 and 4.7% (95% CI 0.1 to 9.5) for NO2.  
Stratification according to P. aeruginosa chronic infection gave almost identical estimates in both groups, but confidence intervals for the infected group 
were wider.  In chronic infected patients relative risks for bronchiectasis exacerbations  associated with a 10 µg/m3 increase in PM10 was 1.115 (95% CI: 
0.989 – 1.257) and for NO2 1.046 (95% CI: 0.937 – 1.169). In P. aeruginosa naïve patients relative risks for bronchiectasis exacerbations  associated with a 10 
µg/m3 increase in PM10 was 1.114 (95% CI 1.056 – 1.175) and for NO2 1.046 (95% CI 0.996 – 1.098) (Figure 3). Similarly, no difference was found between 
groups when stratifying according to Bronchiectasis Severity Index (BSI), Deprivation Index, hospitalization and chronic macrolide use at time of 
exacerbation (Figure 3). There was however a seasonal variation in the association between air pollution and bronchiectasis: higher relative risks were seen 
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during spring (PM10 1.198, 95% CI 1.102 – 1.303; NO2 1.146, 95% CI 1.035 – 1.268) and especially during summer (PM10 2.142, 95% CI 1.785 – 2.570; NO2 
1.352, 95% CI 1.140 – 1.602) as compared to autumn (PM10 0.922, 95% CI 0.828 – 1.027; NO2 1.035, 95% CI 0.927 – 1.156) and winter (PM10 0.984, 95% CI 
0.891 – 1.086; NO2 0.941, 95% CI 0.880 – 1.005)(Figure 3).  
Increasing the maximum lag to 6 days, using an unconstrained lag structure, excluding the cross-basis for temperature and including a cross-basis for 
humidity produced similar results for PM10, with cumulative lag 0-4 effects ranging from 10.0% (95% CI 5.1 to 15.1) to 11.8% (95% CI 6.5 to 17.4) (Table 4). 
Sensitivity analyses also showed robust results for NO2, except for a decrease in cumulative estimates when increasing the maximum lag to 6 days (3.9%, 95 
CI -0.5 to  8.5) and when adding the humidity cross-basis (3.6%, 95% CI -1.1 to 8.6). Same-day (lag 0) estimates from these models, however, remained 
significant  (3.5% and 2.7% respectively). Limiting the analysis to the first exacerbation of each patient did not change the cumulative estimate for PM10 
(11.1, 95% CI -9.2 to 36.0) but resulted in an increase in the estimate for NO2 (9.0, 95% CI -7.3 to 28.1) and a considerable loss in precision for both air 
pollutants.  
 
Discussion 
 
This is to our knowledge the first report on the effect of acute air pollution fluctuations and its effect on exacerbations in a population suffering from 
bronchiectasis. This case-crossover analysis shows that the risk of having an exacerbation increased significantly on days with higher air pollution. For each 
10 µg/m³ increase in PM10 and NO2, the risk of having an exacerbation that same day increased significantly by 4.5% (0..9; 8.3) and 3.2% (0.7; 5.8) 
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respectively. The overall (lag 0-4) increase in the risk of bronchiectasis for a 10 μg/m3 increase in air pollutant concentration was much higher, reaching 
11.2% (95% CI 6.0 to 16.8) for PM10 and 4.7% (95% CI 0.1 to 9.5) for NO2. 
The acute effect of air pollution on bronchiectasis exacerbations is in line with previous research in patient suffering from cystic fibrosis as mentioned in the 
introduction. This is the first analysis looking at the acute effects of air pollution fluctuations in this patient population. The effects of air pollution 
fluctuations seem to be very acute and other researchers have found similar acute effects. Tramuto et al. investigated the effects of air pollution and 
emergency room visits for respiratory symptoms and found that PM10 and NO2, amongst other pollutants, were positively associated in a similar acute 
fashion.27 Further comparable acute effects of air pollution have been shown for other diseases as well. Nawrot et al. determined that air pollution is an 
important trigger for acute myocardial infarction.16 
Subanalysis could not show a predisposition towards the effects of air pollution fluctuations in the defined subgroups. Three subanalyses (P. aeruginosa 
chronic infection, deprivation index and bronchiectasis severity index) showed overlapping confidence intervals. These results seem to corroborate previous 
data from patients with in cystic fibrosis where no statistical significant difference was found in patients chronically infected with P. aeruginosa and those 
not chronically infected.7 
 There was however a difference based on season. Higher risks for bronchiectasis exacerbations were seen during spring and especially summer. Similar 
effects have previously been reported. We previously showed a similar stronger association between exacerbations and air pollution during the warmer 
months of the year in cystic fibrosis patients.7 The reason remains unclear, but one interesting study showed that ambient pollution particles collected 
during spring and summer were more potent at inducing inflammatory cytokines in isolated macrophages of rats compared with samples collected during 
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the winter months.28 Other research shows lower correlations between indoor and outdoor air pollution in colder periods, a period where people tend to 
spend more time indoors.29 Finally, ambient temperature is associated with the prevalence of P aeruginosa and lower lung function in patients with cystic 
fibrosis.30 We speculate that during the colder months exacerbations are likely more viral in origin and less impacted by air pollution and that, during the 
warmer months, bacterial exacerbations are possibly worsened by air pollution or air pollution can have a direct effect on causing exacerbations because 
there are less viral infections during that period. 
Our study has some limitations. One limitation is the lack of data on symptoms and days of symptoms before start of antibiotics as well as the definition we 
used to define an exacerbation. We deemed the need for antibiotic treatment essential, thereby following initial definitions used in large double-blind, 
placebo-controlled trials in bronchiectasis.31,32 However, recently, an expert consensus definition was produced to assist further research. In this new 
definition the patient needs deteriorating symptoms and a decision to make a change in the patients’ bronchiectasis treatment.33 This suggests that non-
antibiotic treatment started due to deteriorating symptoms might also fit the definition of a bronchiectasis exacerbation. This might have resulted in an 
underreporting of the number of exacerbations in our studied population. It needs to be emphasized that this definition is expert opinion and more 
research is needed to fully elucidate the precise definition of an exacerbation.  
Another limitation is the lack of PM2.5 or black carbon data as these weren’t available for the region in enough monitoring stations for that time period. PM10 
consists of PM2.5 and larger particles which are mainly of biological and crustal origin. These particles are capable of penetrating into the lower respiratory 
tract. Research has shown that the smaller PM2.5 fraction is more potent to cause respiratory effects.34 However, high correlations between PM10 and PM2.5 
in the region have been observed. For example, Auchencorth Moss pollution data between June 1st 2012 and December 31st 2015, show a PM10 and PM2.5 
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correlation coefficient of 0.86. Moreover, we added NO2 as black carbon is the particulate matter fraction that correlates best with NO2.35 NO2 is mainly 
emitted by combustion processes (vehicle engines, heating, power generation) and is therefore a good proxy for the mixture of traffic related air pollution. 
A third limitation is the use of outdoor measurements to reflect a patients personal exposure. It is possible that patients will spend more time indoor when 
media alert for high pollution concentrations. We do not believe this will have impacted our study in a significant way as media only alert peak pollution 
concentrations and we studied continuous exposure effects. Research has also shown a good correlation between outdoor and indoor variation. Studies 
show a very good correlation among the day-to-day changes in measurement stations and personal exposure.36,37 We also know from previous data that 
spatial variability in PM10 is less important than temporal variability, as the latter is largely caused by weather changes.38 However, added personal exposure 
based on commute and travelling was not evaluated due to ethical and privacy reasons and could therefore influence the results. 
Ideally to capture spatial and temporal variations we would have used air pollution monitoring sites which were located near where the participants live, were located away 
from local sources (so-called background sites) and operated during the whole time period. During the time period concerned, the only site in Scotland fulfilling these 
requirements was an urban background site in Aberdeen. Therefore, all participants were assigned daily exposures from the same measurement site, giving us the temporal 
signal only. This could be a limitation, however, we don’t believe that this influenced the results because evidence shows that temporal differences are much more 
determining than spatial differences in air pollution.38 
Finally, antibiotics are also prescribed for Gram-negative eradication (predominantly P. aeruginosa) or chronic maintenance treatment. However this had no 
impact on our analysis as the analysis excluded inhaled antibiotics. Also, eradication is only performed by the specialist clinic and is recorded as such. These 
patients were excluded from the dataset. The latter however, represents only a small portion of overall antibiotic use in bronchiectasis, and the application 
of the case-crossover design combined with a high number of exacerbations should overcome this problem for the most part. 
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The four major strengths of this analysis are the large number of patients, the large number of exacerbation events due to the long term follow-up, the 
case-crossover design and the use of distributed lag models. The case-crossover design is widely used for analyzing short-term pollution exposure with acute 
outcomes. A case-crossover analysis is a variant of the case-control in which each subject serves as her or his own control.17 This reduces the influence of 
confounding covariates. The use of distributed lag models is an important strength as their bi-dimensional structure simultaneously describes the 
association along the space of the exposure and in the additional dimension of the lags. This enables the investigation of the temporal pattern of the 
association in one single model and provides an estimate of the “overall” effect of the exposure incorporating delayed effects." 
In our analysis we’ve added deprivation index as a measure for socio-economic status as previous research in bronchiectasis has suggested that socio-
economic status is linked with mortality and exacerbations.39 We found no effect of acute air pollution fluctuations on bronchiectasis pulmonary 
exacerbations. 
To tackle the possible confounding of asthma or COPD, we used the case-crossover analysis as we don't expect that the chronic conditions of a person 
change within the month of exacerbation or any other factor that slowly changes over time. In bronchiectasis, asthma and COPD are important comorbid 
conditions. The existance of asthma in patients with bronchiectasis is associated with an independent increase in risk of bronchiectasis exacerbation and the 
relationship between asthma and pollution has been widely studied.40,41 Similarly, bronchiectasis with associated COPD not only show increased mortality 
compared to bronchiectasis patients without COPD, but bronchiectasis patients with COPD also have higher rates of respiratory infections and 
hospitalization.42,43 Additionally air pollution increases hospitalizations and mortality in COPD.44  
16
 
 
This data adds to an increasing body of data that air pollution increases exacerbation risk in people with a respiratory illness. This presents  a challenge for 
policymakers to address this growing problem. Pollution impacts the health of the whole population and certainly patients with a respiratory condition.  
Further action is needed as European data indicate that current exposure to particulate matter from anthropogenic sources leads to an average loss of 8.6 
months of life expectancy in Europe.45 Data also estimate that over three million life years were lost in the EU (25 countries) in 2000 through exposure to 
PM.45 Estimates of loss in statistical life expectancy in the UK that can be attributed to anthropogenic PM2.5 sources were 6.9 months in 2000 and 4.9 months 
in 2010. Experts estimate that the “no further climate measures” scenario for 2020 will still lead to a loss of life expectancy of 4.5 months in the UK. Previous 
data on chronic exposure combined with our findings on acute pollution fluctuations, suggest that caregivers should inform patients with bronchiectasis on 
the effects of air pollution on their disease. However, it remains to be established if certain interventions (such as mask protection during peak exposure) 
will impact disease morbidity. Our analysis might in part provide an answer to that questions. An intervention that would decrease PM10 by 10 µg/m³ would 
likely lead to a reduction of 11.2% exacerbations. This means that during the study period of 5384 days, a reduction of PM10 by 10 µg/m³ will possibly 
prevent 871 exacerbations. This results in 59 exacerbations possibly prevented per year for a decrease of 10 µg/m³. For NO2, a decrease by 10 µg/m³ will 
likely prevent 25 exacerbations each year. Additionally, further research should also focus to unravel if certain patients have a particular sensitivity to air 
pollution. This could then lead to research testing interventions and patient education programs to improve their health status.  
In conclusion, acute air pollution fluctuations are associated with increased exacerbation risk in patients with bronchiectasis. There was no difference in risk 
between patients stratified according to BSI, deprivation index or the presence of chronic P. aeruginosa infection, but there was a greater effect during the 
spring and especially during the summer months. Air pollution seems to be an important factor in bronchiectasis and patients should be aware of its effects.  
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Table 1: Patient characteristics of the studied population.  
Characteristic Median (IQR) or number (%) 
Total number of patients 430 
Female sex 259 (60.2) 
Age (years)  68 (59-74) 
Number of exacerbations  7319 
Average number of exacerbations per patient  13.5 (7-25) exacerbations/patient/over the study period 
0.91 exacerbations/patient/year 
 
FEV1 % a 71 (50-90) 
Deprivation index b Index 1: 86 (20.5)  
Index 2: 70 (16.7) 
Index 3: 73 (17.4)  
Index 4: 115 (27.5)  
Index 5: 75 (17.9) 
Bronchiectasis Severity Index  median 6 (IQR 4-10) 
 
Mild         (≤4):    121 (28.1) 
Moderate  (5-8):   170 (39.5) 
Severe        (≥9):    139 (32.3) 
Bacteria chronic infection status at enrolment  Haemophilus influenza: 136 (31.6) 
Staphylococcus aureus: 34 (7.9) 
Moraxella catarrhalis: 53 (12.3) 
Enterobacteriaceae: 59 (13.7) 
Pseudomonas aeruginosa: 60 (13.9) 
a Forced Expiratory Volume in one second (N=429). b A lower index indicates higher deprivation (N=419). IQR = Interquartile Range. 
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Table 2: Exposure and exacerbations summary statistics. 
 
Variable Mean SD Min Max 
Daily number of exacerbationsa 3.1 3.7 0.0 42.0 
Exposure on case days 
    
Temperature (°C)a 8.1 5.1 -11.5 21.3 
PM10 (μg/m3)a 15.8 9.4 1.0 82.6 
NO2 (μg/m3)b 25.5 13.6 1.7 85.7 
Exposure difference between case days and average over control daysc 
Temperature (°C)a 10.2 8.9 0.0 53.7 
PM10 (μg/m3)a 7.2 7.1 0.0 62.8 
NO2 (μg/m3)b 2.3 1.8 0.0 13.6 
 
Summary statistics for daily bronchiectasis exacerbations, mean temperature and air pollution levels, and for the absolute differences between the daily levels 
of each variable (case days) and the average levels over the control days.  
aSummary statistics for cases with PM10 data available (N exacerbations = 6741; Total number of patients = 430).  
bSummary statistics for cases with NO2 data available (N exacerbations = 6248; Total number of patients = 426).  
cThe relevant exposure term in a case-crossover design (23).  Min indicates minimum; Max, maximum. 
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Figure 1. Exposure-lag-response surfaces for the association between bronchiectasis exacerbations and exposure.  
  
Exposure-lag-response surfaces for the association between bronchiectasis exacerbations and exposure to PM10 (left) and NO2 (right). Relative risks (RR) are 
relative to the reference value of 10 µg/m3 (bold line). Lag 0 is the day of exacerbation. Lag 1 is the day before the exacerbation. Lag 2, Lag 3 and Lag 4 are 2, 
3 and 4 days before the exacerbation. RR = relative risk; PM10 = particulate matter with a diameter smaller than 10 µm. 
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Figure 2. Lag-specific relative risks for bronchiectasis exacerbations  
 
Lag-specific relative risks (RR, with 95% confidence interval) for bronchiectasis exacerbations associated with a 10 µg/m3 increase in PM10 (left) and NO2 (right).  
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Table 3. Cumulative effects of PM10 and NO2 on bronchiectasis exacerbations along the lag days.  
Lay (day) PM10 NO2 
0 4.5 (0.9; 8.3) 3.2 (0.7; 5.8) 
0-1 7.7 (3.7; 11.8) 4.4 (1.3; 7.5) 
0-2 9.7 (5.4; 14.2) 4.5 (0.9; 8.1) 
0-3 10.8 (6.1; 15.7) 4.4 (0.4; 8.5) 
0-4 11.2 (6.0; 16.8) 4.7 (0.1; 9.5) 
 
Estimates represent the percent change (95% confidence interval) in bronchiectasis exacerbations for 
a 10 µg/m3 increase in air pollutant concentration. 
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Table 4 Sensitivity analysis estimates for the cumulative lag 0-4 effects of PM10 and NO2 on 
bronchiectasis exacerbations.  
Change in main modelb PM10 NO2 
None 11.2 (6.0; 16.8) 4.7 (0.1; 9.5) 
Maximum lag = 6 days 11.6 (6.5; 16.9) 3.9 (-0.5; 8.5) 
Unconstrained lag model 11.8 (6.5; 17.4) 4.3 (-0.2; 9.1) 
No temperature correction 
 
 
10.0 (5.1; 15.1) 5.0 (0.7; 9.5) 
Humidity correction 11.3 (5.8 ; 17.2) 3.6 (-1.1 : 8.6) 
First event only 11.1 (-9.2; 36.0) 9.0 (-7.3; 28.1) 
Estimates represent the percent change (95% confidence interval) in bronchiectasis exacerbations for 
a 10 µg/m3 increase in air pollutant concentration. b In the main analysis recurrent event data were 
pooled, and the distributed lag model has a maximum lag of 4 days, 3 df for the lag-response 
function, and is adjusted for mean temperature (cross-basis function with a maximum lag of 25 days, 
5 df for the temperature-response function, and 6 df for the lag-response function). 
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Figure 3: Association between bronchiectasis exacerbations and PM10 and NO2 air pollution, overall 
and by subpopulation 
 
Cumulative relative risks (RR, with 95% confidence interval) for bronchiectasis exacerbations  
associated with a 10 µg/m3 increase in PM10 (grey circles) and NO2 (black diamonds) stratified according 
to Pseudomonas aeruginosa culture positivity, bronchiectasis severity index, deprivation index, 
hospitalization, chronic macrolide use at time of exacerbation, and season. 
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